Get the Stockscreener App
20.68
0.67%
-0.14
After Hours:
20.68
Enliven Therapeutics Inc stock is traded at $20.68, with a volume of 449.18K.
It is down -0.67% in the last 24 hours and up +3.61% over the past month.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
See More
Previous Close:
$20.82
Open:
$21.18
24h Volume:
449.18K
Relative Volume:
0.96
Market Cap:
$1.22B
Revenue:
-
Net Income/Loss:
$-85.21M
P/E Ratio:
-10.94
EPS:
-1.89
Net Cash Flow:
$-68.53M
1W Performance:
+1.87%
1M Performance:
+3.61%
6M Performance:
+25.26%
1Y Performance:
-25.90%
1-Day Range:
$20.40
$21.28
1-Week Range:
$20.00
$21.81
52-Week Range:
$13.30
$30.03
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Name
Enliven Therapeutics Inc
Sector
Industry
Phone
720-647-8519
Address
6200 LOOKOUT ROAD, BOULDER
Compare ELVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
20.68 | 1.23B | 0 | -85.21M | -68.53M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Initiated | Goldman | Buy |
| Dec-13-24 | Initiated | BTIG Research | Buy |
| Sep-09-24 | Initiated | H.C. Wainwright | Buy |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-09-24 | Initiated | Mizuho | Buy |
| Mar-29-23 | Initiated | Jefferies | Buy |
View All
Enliven Therapeutics Inc Stock (ELVN) Latest News
Heatmap analysis for Enliven Therapeutics Inc. and competitorsJuly 2025 EndofMonth & Risk Adjusted Buy and Sell Alerts - newser.com
Automated trading signals detected on Enliven Therapeutics Inc.Trade Exit Summary & Consistent Return Investment Signals - newser.com
Enliven Therapeutics Inc. recovery potential after sell off2025 Top Decliners & Weekly Top Gainers Alerts - newser.com
Chart based exit strategy for Enliven Therapeutics Inc.July 2025 Fed Impact & Daily Stock Trend Reports - newser.com
Enliven Therapeutics (NASDAQ:ELVN) Trading 6.1% HigherHere's Why - MarketBeat
Insider Selling: Enliven Therapeutics (NASDAQ:ELVN) COO Sells 6,667 Shares of Stock - MarketBeat
Volatility clustering patterns for Enliven Therapeutics Inc.Rate Cut & Free Weekly Watchlist of Top Performers - newser.com
What the charts say about Enliven Therapeutics Inc. todayWeekly Stock Recap & Weekly High Return Forecasts - newser.com
Is a relief rally coming for Enliven Therapeutics Inc. holdersWeekly Trade Analysis & High Accuracy Swing Entry Alerts - newser.com
Long term hold vs stop loss in Enliven Therapeutics Inc.2025 Top Decliners & Daily Profit Focused Stock Screening - newser.com
Enliven Therapeutics (NASDAQ:ELVN) Receives Sell (D-) Rating from Weiss Ratings - MarketBeat
Using Ichimoku Cloud for Enliven Therapeutics Inc. technicals2025 Analyst Calls & Consistent Growth Equity Picks - newser.com
Enliven Therapeutics COO Patel sells $133,992 in stock By Investing.com - Investing.com South Africa
Enliven Therapeutics COO Patel sells $133,992 in stock - Investing.com
Short interest data insights for Enliven Therapeutics Inc.Market Activity Report & Real-Time Volume Spike Alerts - newser.com
What moving averages say about Enliven Therapeutics Inc.Market Activity Report & Low Risk Growth Stock Ideas - newser.com
Why retail investors favor Enliven Therapeutics Inc. stockQuarterly Growth Report & Free Safe Capital Growth Stock Tips - newser.com
Is now a turning point for Enliven Therapeutics Inc.2025 Volatility Report & Smart Money Movement Alerts - newser.com
Enliven Therapeutics stock falls after pricing capital raise of $200M via securities offering - MSN
Developing predictive dashboards with Enliven Therapeutics Inc. dataStop Loss & Weekly Sector Rotation Insights - newser.com
Will Enliven Therapeutics Inc. rebound enough to break evenJuly 2025 Snapshot & Reliable Intraday Trade Alerts - newser.com
Top chart patterns to watch in Enliven Therapeutics Inc.July 2025 Retail & Risk Managed Investment Signals - newser.com
Will Enliven Therapeutics Inc. stock recover after recent drop2025 Earnings Impact & Precise Swing Trade Alerts - newser.com
Benjamin Hohl Sells 3,250 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Insider Sells $81,000.00 in Stock - MarketBeat
Enliven Therapeutics CFO sells $22,524 in stock - MSN
Enliven Therapeutics (NASDAQ:ELVN) CEO Samuel Kintz Sells 3,700 Shares - MarketBeat
Enliven Therapeutics Inc Stock (ELVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Enliven Therapeutics Inc Stock (ELVN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hohl Benjamin | CHIEF FINANCIAL OFFICER |
Sep 29 '25 |
Option Exercise |
2.48 |
3,250 |
8,060 |
26,250 |
| Hohl Benjamin | CHIEF FINANCIAL OFFICER |
Sep 29 '25 |
Sale |
20.40 |
3,250 |
66,291 |
23,000 |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER |
Sep 26 '25 |
Sale |
20.25 |
4,000 |
81,005 |
927,688 |
| Kintz Samuel | PRESIDENT AND CEO |
Sep 26 '25 |
Sale |
20.06 |
3,700 |
74,228 |
915,392 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):